Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP) — Market Cap & Net Worth
Market Cap & Net Worth: Rapport Therapeutics, Inc. Common Stock (RAPP)
Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP) has a market capitalization of $2.11 Billion ($2.11 Billion) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5976 globally and #1936 in its home market, demonstrating a -7.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Rapport Therapeutics, Inc. Common Stock's stock price $44.00 by its total outstanding shares 47978286 (47.98 Million). Also see RAPP total assets for a full breakdown of the balance sheet.
Rapport Therapeutics, Inc. Common Stock Market Cap History: 2024 to 2026
Rapport Therapeutics, Inc. Common Stock's market capitalization history from 2024 to 2026. Data shows growth from $851.13 Million to $2.11 Billion (39.08% CAGR). Also see Rapport Therapeutics, Inc. Common Stock (RAPP) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Rapport Therapeutics, Inc. Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.68 Trillion | 0.08% | #167 of 976 |
|
NASDAQ Composite
IXIC
|
$41.94 Trillion | 0.01% | #681 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.89 Trillion | 0.11% | #101 of 263 |
Weight: Rapport Therapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Rapport Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Rapport Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Rapport Therapeutics, Inc. Common Stock (RAPP) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RAPP by Market Capitalization
Companies near Rapport Therapeutics, Inc. Common Stock in the global market cap rankings as of September 16, 2026. Review RAPP tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Rapport Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #338 globally with a market cap of $80.28 Billion USD.
- CSL Ltd (AU:CSL): Ranked #463 globally with a market cap of $58.90 Billion USD ( AU$83.24 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $519.51 |
| #338 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.28 Billion | $793.74 |
| #463 | CSL Ltd | AU:CSL | $58.90 Billion | AU$171.57 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $146.69 |
Rapport Therapeutics, Inc. Common Stock Historical Marketcap From 2024 to 2026
Between 2024 and today, Rapport Therapeutics, Inc. Common Stock's market cap moved from $851.13 Million to $ 2.11 Billion, with a yearly change of 39.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.11 Billion | +45.02% |
| 2025 | $1.46 Billion | +71.03% |
| 2024 | $851.13 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of Rapport Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.11 Billion USD |
| MoneyControl | $2.11 Billion USD |
| MarketWatch | $2.11 Billion USD |
| marketcap.company | $2.11 Billion USD |
| Reuters | $2.11 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containin… Read more